Comparison of paclitaxel and carboplatin with ifosfamide and cisplatin for the treatment of ovarian carcinosarcoma

Santacruz, Mayra; Gehrig, P.A.; Skinner, Elizabeth N.; Boggess, John F.; Fowler, Wesley C.; Le, Linda Van

doi:10.1200/jco.2004.22.90140.5116

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a similar but much smaller report, patients treated with platinum–paclitaxel‐based chemotherapy ( n = 6) seemed to have similar outcome to those treated with platinum–ifosfamide‐based chemotherapy ( n = 8) (53) . In another small retrospective study ( n = 11), OCS patients who received postoperative carboplatin–paclitaxel had similar outcome to those who received cisplatin–ifosfamide, which was also more toxic (69) . In a recent small ( n = 8), prospective study in which patients with primary or recurrent OCS were treated with ifosfamide and cisplatin, an encouraging MS of 21 months was reported (56) .…”

Section: Treatmentmentioning

confidence: 87%

Current management of ovarian carcinosarcoma

Mano

Rosa

Azambuja

et al. 2007

Int J Gynecol Cancer

View full text Add to dashboard Cite

Ovarian carcinosarcomas (OCS), also known as malignant mixed müllerian tumors, are uncommon malignancies that carry a poor prognosis. The presentation of OCS is usually indistinguishable from that of epithelial ovarian cancer. Due to its low frequency, prospective trials have been difficult to perform, but there is evidence that OCS are sensitive to platinum-based chemotherapy. Recent studies have shown encouraging results with platinum-ifosfamide and platinum-taxane schedules, which are usually considered the treatment of choice. However, poor performance status at presentation is also a common problem, so that many patients may be unsuitable for combination chemotherapy but may still benefit from single-agent platinum or ifosfamide or, occasionally, from nonplatinum schedules such as ifosfamide plus paclitaxel. Aggressive cytoreductive surgery appears to have a positive impact on outcome and should probably be offered to most patients. However, this procedure has been associated with higher rates of complication in OCS and should only be attempted by experienced (gynecological) surgeons in centers with expertise in the management of gynecological malignancies.

show abstract

Section: Treatmentmentioning

confidence: 87%